On this episode of Stock Movers:
- Strategy (MSTR) shares are mixed. On Friday, Billionaire Michael Saylor on Friday defended Strategy’s approach to Bitcoin.
- Netflix (NFLX) shares rise. Investors weigh the company’s push into live sports despite a thinning slate of mega-hit series.
- Moderna (MRNA) shares rise. Piper Sandler raised the firm's price target on Moderna to $77 from $69 and keeps an Overweight rating on the shares.

On this episode of Stock Movers: - Strategy (MSTR) shares are mixed. On Friday, Billionaire Michael Saylor on Friday defended Strategy&rsquo;s approach to Bitcoin. - Netflix (NFLX) shares rise. Investors weigh the company&rsquo;s push into live sports despite a thinning slate of mega-hit series. - Moderna (MRNA) shares rise. Piper Sandler raised the firm's price target on Moderna to $77 from $69 and keeps an Overweight rating on the shares.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. 

Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for five-minute conversations on today's biggest winners and losers in the stock market.&nbsp;
Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Strategy Mixed, Netflix Rises, Moderna Rises After Price target Raised

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/1fa040dc-c6d4-4f92-a1ea-b47500fbce6a/transcript

On this episode of Stock Movers:

- Onsemi (ON) shares ended the week lower following news the US chipmaker has agreed to buy Synaptics Inc., a firm that specializes in semiconductors for smart devices.

- Bio-Techne (TECH) shares ended the week higher after Merck agreed to buy Bio-Techne Corporation for about $11.3 billion to bolster its life-science business, marking the German pharma and technology group’s biggest acquisition in more than a decade.

- Oracle (ORCL) stock plummeted this week as concerns mount over the company's debt-load and following the news reported by the New York Times that OpenAI could delay its IPO until next year.

On this episode of Stock Movers:
- Onsemi (ON) shares ended the week lower following news the US chipmaker has agreed to buy Synaptics Inc., a firm that specializes in semiconductors for smart devices.
- Bio-Techne (TECH) shares ended the week higher after Merck agreed to buy Bio-Techne Corporation for about $11.3 billion to bolster its life-science business, marking the German pharma and technology group&rsquo;s biggest acquisition in more than a decade.
- Oracle (ORCL) stock plummeted this week as concerns mount over the company's debt-load and following the news reported by the New York Times that OpenAI could delay its IPO until next year.

Onsemi, Oracle End Week Lower, Biotechne Jumps

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/978c2352-46d9-4778-8e4b-b4750163ae07/transcript

On this episode of Stock Movers:

- Shares of Goldman Sachs (GS) slide after the New York Times reported that bankers advising OpenAI cautioned that volatility in tech stocks could dent enthusiasm for an offering.

- Onsemi (ON) shares slide following news the US chipmaker has agreed to buy Synaptics Inc., a firm that specializes in semiconductors for smart devices.

- Darden Restaurants (DRI) dips slightly after the restaurant chain operator reported worse-than-expected sales performance for Olive Garden, while the LongHorn’s unit topped the Street view.

On this episode of Stock Movers:
- Shares of Goldman Sachs (GS) slide after the New York Times reported that bankers advising OpenAI cautioned that volatility in tech stocks could dent enthusiasm for an offering.
- Onsemi (ON) shares slide following news the US chipmaker has agreed to buy Synaptics Inc., a firm that specializes in semiconductors for smart devices.
- Darden Restaurants (DRI) dips slightly after the restaurant chain operator reported worse-than-expected sales performance for Olive Garden, while the LongHorn&rsquo;s unit topped the Street view.

Banks Slide on OpenAI IPO Warning, Onsemi, Darden Lower

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/455e52be-e815-4a04-970d-b475013dbba8/transcript

On this episode of Stock Movers:
Synaptics (SYNA) shares rise. Onsemi has agreed to buy Synaptics Inc. in an all-stock deal that values the company at about $6.2 billion. The transaction has a total enterprise value including debt of roughly $7 billion and is expected to close in mid-2027, subject to approvals.
Lumentum (LITE) shares fall. U.S. optical communication stocks dropped. This comes as Semiconductor stocks are broadly lower.
Acadia Pharma (ACAD) shares climb as much as 12%, the most intraday since May 2025, after the drugmaker said the European Medicines Agency’s CHMP issued a positive opinion for its drug to treat symptoms of Rett syndrome and recommended granting a marketing authorization.

On this episode of Stock Movers: Synaptics (SYNA) shares rise. Onsemi has agreed to buy Synaptics Inc. in an all-stock deal that values the company at about $6.2 billion. The transaction has a total enterprise value including debt of roughly $7 billion and is expected to close in mid-2027, subject to approvals. Lumentum (LITE) shares fall. U.S. optical communication stocks dropped. This comes as Semiconductor stocks are broadly lower. Acadia Pharma (ACAD) shares climb as much as 12%, the most intraday since May 2025, after the drugmaker said the European Medicines Agency&rsquo;s CHMP issued a positive opinion for its drug to treat symptoms of Rett syndrome and recommended granting a marketing authorization.

Synaptics Rises, Lumentum Falls, Acadia Pharma Jumps on Positive CHMP Drug Opinion

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/4b291a27-b072-4caf-a2fc-b47500ef9ba9/transcript

Strategy Mixed, Netflix Rises, Moderna Rises After Price target Raised

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips